Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Carboplatin, Etoposide, Ifosfamide, Rituximab in patients with Non-Hodgkin Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients.